GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » Short Percentage of Float

Shaperon (XKRX:378800) Short Percentage of Float


View and export this data going back to 2022. Start your Free Trial

What is Shaperon Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Shaperon's Short Percentage of Float

For the Biotechnology subindustry, Shaperon's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shaperon's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shaperon's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Shaperon's Short Percentage of Float falls into.


;
;

Shaperon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » Short Percentage of Float
Comparable Companies
XKRX:388870 XKRX:049960 XKRX:296160 XKRX:348150 XKRX:261780 XKRX:067370 XKRX:166480 XKRX:185490 XKRX:314130 XKRX:348080 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373
Website
http://www.shaperon.com
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.

Shaperon Headlines

No Headlines